124.05 -0.29 (-0.23%)
After hours: 4:04PM EST
|Bid||124.47 x 800|
|Ask||124.50 x 800|
|Day's range||123.39 - 125.00|
|52-week range||78.90 - 130.20|
|Beta (3Y monthly)||0.78|
|PE ratio (TTM)||41.17|
|Earnings date||12 Feb 2020 - 17 Feb 2020|
|Forward dividend & yield||0.66 (0.53%)|
|1y target est||137.00|
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
The addition of ZNLabs expands Zoetis’ reference laboratory capabilities in the U.S.
Zoetis (ZTS) delivered earnings and revenue surprises of 5.62% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
With the addition of reference laboratory services, Zoetis now can provide more comprehensive diagnostics products and services as an enhanced value to veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Reference laboratories and point-of-care diagnostic testing are highly synergistic, offering veterinarians a single source for a full spectrum of tests, as well as access to the expertise of Board-certified specialists and pathologists to support test results.
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.